[1] WALLACE Z S, ZHANG Y, PERUGINO C A, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts[J]. Ann Rheum Dis, 2019,78(3):406-412. [2] 尚丽婧, 李芳瑜. IgG4相关性疾病的研究进展[J]. 疑难病杂志,2022,21(4):436-440. [3] UMEHARA H, OKAZAKI K, MASAKI Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012,22(1):21-30. [4] 章士正. 胰腺外脏器IgG4相关病变的影像学表现[J]. 放射学实践,2019,34(7):714-722. [5] KAWA S, ITO T, WATANABE T, et al. The utility of serum IgG4 concentrations as a biomarker[J]. Int J Rheumatol, 2012,2012:198314. [6] BAI Z, ZHOU T, YU Z, et al. Clinical value of (18)F-FDG PET/CT in IgG4-related disease[J]. Ann Nucl Med, 2022,36(7):651-660. [7] WALLACE Z S, NADEN R P, CHARI S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J]. Ann Rheum Dis, 2020,79(1):77-87. [8] TANG C, CHUA W M, CHENG L, et al. (18)F-FDG PET/CT manifestations of IgG4-related disease[J]. Br J Radiol, 2021,94(1124):20210105. [9] CHEN M, TANG C, FONG W, et al. Semi-quantitative indices of 2-[(18)F] FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response[J]. EJNMMI Res, 2023,13(1):22. [10] 丁航, 刘源, 张连峰,等. IgG4相关性疾病的临床特征研究[J]. 中国全科医学,2022,25(5):584-588. [11] 陈雨, 张文. 解读首个《IgG4相关性疾病管理和治疗的国际共识指南》[J]. 中华临床免疫和变态反应杂志,2015,9(3):159-162. |